Johnson & Johnson (NYSE: JNJ) (the “Company”) has announced the successful completion of its acquisition of Halda Therapeutics OpCo, Inc. (“Halda”), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. With this acquisition, Johnson & Johnson adds HLD-0915, a clinical-stage therapy for prostate cancer, building on the Company’s nearly two decades of innovation in this disease area.
Read the full article: Johnson & Johnson Completes Acquisition of Halda Therapeutics //
Source: https://www.businesswire.com/news/home/20251229435345/en/Johnson-Johnson-completes-acquisition-of-Halda-Therapeutics-and-its-novel-platform-to-revolutionize-cancer-treatment-and-enable-next-generation-oral-therapies